Literature DB >> 28288438

Epidemiology of pharmaceutically treated depression and treatment resistant depression in Taiwan.

Daniel Fife1, Yu Feng2, Michael Yao-Hsien Wang3, Chee-Jen Chang4, Chia-Yih Liu5, Hsiao-Ting Juang6, Wesley Furnback7, Jaskaran Singh8, Bruce Wang9.   

Abstract

Epidemiologic data on treatment resistant depression (TRD) in Asia-Pacific countries are limited. We estimated the incidence of TRD in Taiwan using a cohort of 704,265 adults randomly sampled from Taiwan's National Health Insurance Research database for 2005. TRD was defined as a patient having pharmaceutically treated depression (PTD) not adequately responding to 2 antidepressant (AD) regimens, i.e., AD regimens that were followed by other AD regimens. Among 2751 PTD subjects, 576 (20.94%, 95% CI: 19.46, 22.49) developed TRD, a proportion similar to that in North American studies. TRD incidence was 0.82 (95% CI: 0.75, 0.89) cases /1000 population in 2005, increased with age, and was higher in females than in males. SSRI's were the most frequently used ADs. Augmentation with antipsychotics was common. The median time from PTD onset (first AD medication) to TRD onset was 416 days but psychiatrists practicing in Taiwan indicated they would switch within <=3 months if an AD medication was not effective. We therefore repeated the analysis with a 6 months cap on time from onset of PTD to TRD. In this supplemental, post-hoc, analysis, 68 PTD subjects, 2.47%, (95% CI: 1.94, 3.10) developed TRD; i.e., 0.10 (95% CI: 0.08, 0.12) incident cases/1000 population.
Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Incidence; Major depressive disorder; Prevalence; Treatment resistant depression, antidepressant medication

Mesh:

Substances:

Year:  2017        PMID: 28288438     DOI: 10.1016/j.psychres.2017.03.006

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  20 in total

1.  Roles of sedative-hypnotics in patients with recurrent major depressive disorder: a nationwide population-based 14-year follow-up study in Taiwan.

Authors:  Kuo-Hsuan Chung; Tzu-Yin Lee; Min-Huey Chung
Journal:  Psychopharmacology (Berl)       Date:  2021-02-25       Impact factor: 4.530

2.  Estimating Prevalence and Healthcare Utilization for Treatment-Resistant Depression in Japan: A Retrospective Claims Database Study.

Authors:  Jörg Mahlich; Sunny Tsukazawa; Frank Wiegand
Journal:  Drugs Real World Outcomes       Date:  2018-03

3.  Risk and risk factors for disability pension among patients with treatment resistant depression- a matched cohort study.

Authors:  Heidi Taipale; Johan Reutfors; Antti Tanskanen; Lena Brandt; Jari Tiihonen; Allitia DiBernardo; Ellenor Mittendorfer-Rutz; Philip Brenner
Journal:  BMC Psychiatry       Date:  2020-05-13       Impact factor: 3.630

4.  Treatment resistant depression incidence estimates from studies of health insurance databases depend strongly on the details of the operating definition.

Authors:  Daniel Fife; Jenna Reps; M Soledad Cepeda; Paul Stang; Margaret Blacketer; Jaskaran Singh
Journal:  Heliyon       Date:  2018-07-26

5.  Treatment-resistant depression as risk factor for substance use disorders-a nation-wide register-based cohort study.

Authors:  Philip Brenner; Lena Brandt; Gang Li; Allitia DiBernardo; Robert Bodén; Johan Reutfors
Journal:  Addiction       Date:  2019-04-15       Impact factor: 6.526

6.  Epidemiology of pharmaceutically treated depression and treatment resistant depression in South Korea.

Authors:  Namwoo Kim; Sung Joon Cho; Hyeyoung Kim; Se Hyun Kim; Hyun Jeong Lee; C Hyung Keun Park; Sang Jin Rhee; Daewook Kim; Bo Ram Yang; So-Hyun Choi; GumJee Choi; MinJung Koh; Yong Min Ahn
Journal:  PLoS One       Date:  2019-08-23       Impact factor: 3.240

7.  Finding treatment-resistant depression in real-world data: How a data-driven approach compares with expert-based heuristics.

Authors:  M Soledad Cepeda; Jenna Reps; Daniel Fife; Clair Blacketer; Paul Stang; Patrick Ryan
Journal:  Depress Anxiety       Date:  2017-12-15       Impact factor: 6.505

8.  A register-based approach to identifying treatment-resistant depression-Comparison with clinical definitions.

Authors:  David Hägg; Philip Brenner; Johan Reutfors; Gang Li; Allitia DiBernardo; Robert Bodén; Lena Brandt
Journal:  PLoS One       Date:  2020-07-30       Impact factor: 3.240

9.  All-cause mortality in patients with treatment-resistant depression: a cohort study in the US population.

Authors:  Gang Li; Daniel Fife; Grace Wang; John J Sheehan; Robert Bodén; Lena Brandt; Philip Brenner; Johan Reutfors; Allitia DiBernardo
Journal:  Ann Gen Psychiatry       Date:  2019-09-30       Impact factor: 3.455

10.  Substance use disorders and risk for treatment resistant depression: a population-based, nested case-control study.

Authors:  Philip Brenner; Lena Brandt; Gang Li; Allitia DiBernardo; Robert Bodén; Johan Reutfors
Journal:  Addiction       Date:  2019-12-16       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.